Abstract:Despite significant advances in the treatment of cutaneous melanoma (hereafter melanoma), the prognosis remains less favorable due to therapeutic resistance, which is presumably linked to epigenetic dysregulation. We hypothesized that the histone lysine demethylase KDM4B could play a pivotal role in controlling therapy‐resistant melanoma. To validate our hypothesis, we retrieved RNA sequencing data from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) program and observed upregulation of KDM4B in both primary and metastatic melanoma, which was associated with poor survival. To explore its role, we used murine B16, human SK‐MEL‐5, and G‐361 melanoma cells as in vitro models of melanoma. We found that KDM4B inhibition using NCGC00244536 increased global levels of H3K9me3 and downregulated the expressions of cell cycle progression–related genes Cdk1, Cdk4, Ccnb1, and Ccnd1. Moreover, genetic ablation of KDM4B or its chemical inhibition using NCGC00244536 reduced p53 production by upregulating MDM2, which enhances the proteolytic degradation of p53. Interestingly, despite the reduction of p53, these interventions augmented apoptosis and senescence‐induced cell death by activating pathways downstream of p53, as evidenced by reduced levels of pro‐survival Bcl‐2 and Bcl‐xL proteins and increased production of pro‐apoptotic cleaved caspase‐3, caspase‐7, Bax, and the senescence inducer Cdkn1a. Compared to the FDA‐approved anti‐melanoma agent dacarbazine, NCGC00244536 exhibited more pronounced cytotoxic and antiproliferative effects in melanoma cells. Importantly, NCGC00244536 demonstrated minimal cytotoxicity to low Kdm4b‐expressing mouse embryonic fibroblasts. In conclusion, our findings suggest that KDM4B inhibition can override the antitumor effect of p53, and potentially serve as a therapeutic strategy for melanoma.

Histone Demethylase Kdm6b Regulates 1,25-Dihydroxyvitamin D3-Induced Senescence In Glioma Cells

Inhibition of Human Glioblastoma Multiforme Cells by 10,11-Dehydrocurvularin Through the MMP-2 and PI3K/AKT Signaling Pathways

Hspb1 Enhances Sirt2-Mediated G6pd Activation And Promotes Glioma Cell Proliferation

Inhibition of lysine-specific demethylase LSD1 induces senescence in Glioblastoma cells through a HIF-1α-dependent pathway

Histone Demethylase Lysine Demethylase 5B in Development and Cancer

The pharmacological role of histone demethylase JMJD3 inhibitor GSK-J4 on glioma cells

The histone H3 Lys 27 demethylase KDM6B promotes migration and invasion of glioma cells partly by regulating the expression of SNAI1.

KDM4B Histone Demethylase Inhibition Attenuates Tumorigenicity of Malignant Melanoma Cells by Overriding the p53‐Mediated Tumor Suppressor Pathway

A Selective Histone Deacetylase Inhibitor Induces Autophagy and Cell Death via SCNN1A Downregulation in Glioblastoma Cells

Histone Deacetylase SIRT6 Inhibits Glioma Cell Growth Through Down-Regulating NOTCH3 Expression.

Epigenetic regulation of wnt pathway antagonists in human glioblastoma multiforme

KDM4 Orchestrates Epigenomic Remodeling of Senescent Cells and Potentiates the Senescence-Associated Secretory Phenotype

Anti-tumor effects of vitamin D in glioblastoma: mechanism and therapeutic implications

Histone Deacetylase HDAC4 Promotes the Proliferation and Invasion of Glioma Cells.

Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG

Regulation of the JMJD3 (KDM6B) histone demethylase in glioblastoma stem cells by STAT3

TDP-43/HDAC6 axis promoted tumor progression and regulated nutrient deprivation-induced autophagy in glioblastoma

Vitamin D3 suppresses the cholesterol homeostasis pathway in patient‐derived glioma cell lines

DNA methylation protects cancer cells against senescence

HBP1-mediated transcriptional regulation of DNA methyltransferase 1 and its impact on cell senescence.